TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00576836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Thymus Tissue Implantation (CTTI)
Description: Thymus tissue (from unrelated donor), thymus donor, and thymus donor's birth mother screened for safety. CTTI was done under general anesthesia. Cultured thymus tissue was implanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not \>18 grams/m2 body surface area (1.0 grams/kg body weight). At time of CTTI, skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy was done to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-CTTI, subjects followed by immune evaluations, using blood samples.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultured Thymus Tissue Implantation with Parathyroid Transplantation
Description: Parental parathyroid donors screened for eligibility and safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most Human Leukocyte Antigens (HLA) alleles with thymus donor. Parathyroid harvest \& transplant preferably done at same time as CTTI. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of CTTI.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced \& placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
Study: NCT01691391

Intervention type: BEHAVIORAL
Intervention: (Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles
Description: Patients will be treated with cetuximab or panitumumab. Two \[18F-\]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin and tumor biopsies for kinase activity profiles.
Study: NCT02705209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cayenne Pepper Cataplasm
Description: Poultice of Kaolin, Cayenne Peppfer (5%) and Water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cataplasm
Description: Poultice of Kaolin and Water
Study: NCT01050907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: 2.5 mg/kg/day for 28 days
Study: NCT04315987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NestaCell®
Description: A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
Study: NCT04193878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled budesonide and formoterol
Description: aerosolized doses of budesonide (1.0 mg/2 ml) and formoterol (20 mg/2 ml) twice daily for up to 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: aerosolized saline (4 ml of 0.9% saline) twice daily for up to 5 days
Study: NCT03937284

Intervention type: OTHER
Intervention: Patients not treated

Intervention type: OTHER
Intervention: Patients not treated
Study: NCT03240757

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: All subjects received a standard 75-g OGTT to assess eligibility for the study. The 19 subjects matching the inclusion criteria completed 2 experimental trials: resting and exercise. During the resting trial, all subjects underwent an OGTT (50-g: A) and 3 meal tolerance tests \[one for each breakfast tested: B1 = milk (125ml) and cereals (30g); B2 = milk (220ml), apple (200g) and chocolate cream-filled sponge cake (30g); B3 = milk (125ml), apple (150g), bread (50g) and hazelnut chocolate cream (15g)\]. In the exercise trial, 100 minutes after the glucose/meal ingestion, participants cycled for 20 min at 40% of maximum oxygen uptake.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: All subjects received a standard 75-g OGTT to assess eligibility for the study. The 19 subjects matching the inclusion criteria completed 2 experimental trials: resting and exercise. During the resting trial, all subjects underwent an OGTT (50-g: A) and 3 meal tolerance tests \[one for each breakfast tested: B1 = milk (125ml) and cereals (30g); B2 = milk (220ml), apple (200g) and chocolate cream-filled sponge cake (30g); B3 = milk (125ml), apple (150g), bread (50g) and hazelnut chocolate cream (15g)\]. In the exercise trial, 100 minutes after the glucose/meal ingestion, participants cycled for 20 min at 40% of maximum oxygen uptake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: aerobic exercise at 40% of VO2max, for 20 minutes
Study: NCT02401412

Intervention type: DEVICE
Group type: OTHER
Intervention: Test Ostomy Barrier

Intervention type: DEVICE
Group type: OTHER
Intervention: Control Ostomy Barrier
Study: NCT00986440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: CS-7017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03872232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe/Rosuvastatin
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: PO, Once daily(QD), 8weeks
Study: NCT01033617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of stem cells at time of coronary artery bypass grafting
Description: Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection of stem cells at time of coronary artery bypass grafting
Description: Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
Study: NCT04256434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinalbuphine sebacate
Description: 150 mg Dinalbuphine sebacate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine HCl
Description: 20 mg Nalbuphine
Study: NCT03088722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training CHEWs to provide contraceptive implants
Description: Training CHEWs to provide contraceptive implants
Study: NCT01869075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge Translation (KT) toolkit
Description: KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge Translation (KT) toolkit
Description: KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge Translation (KT) toolkit
Description: KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff
Study: NCT02847351

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arabinoxylan Diet
Description: 19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of weight steady state. Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX).~Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Arabinoxylan Diet
Description: 19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of weight steady state. Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX).~Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT).
Study: NCT04625998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced CATCH Elementary School Program
Description: Enhanced CATCH Elementary School Program is a Coordinated School Health Program that includes the CATCH Coordination Guide.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATCH Early Childhood (CEC)
Description: Implementation of the CATCH Early Childhood coordinated nutrition and physical activity program for Early Care and Education (ECE) centers.
Study: NCT02959567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aqueduct 100 dilation
Study: NCT03140774

Intervention type: BIOLOGICAL
Intervention: Previously exposed to Ebola vaccine
Description: Exposure of interest: participants must have had one or more previous Ebola vaccines, Ad26.ZEBOV , MVA-BN-Filo or r-VSV-ZEBOV to enter the study.

Intervention type: BIOLOGICAL
Intervention: Previously exposed to Ebola vaccine
Description: Exposure of interest: participants must have had one or more previous Ebola vaccines, Ad26.ZEBOV , MVA-BN-Filo or r-VSV-ZEBOV to enter the study.

Intervention type: BIOLOGICAL
Intervention: Previously exposed to Ebola vaccine
Description: Exposure of interest: participants must have had one or more previous Ebola vaccines, Ad26.ZEBOV , MVA-BN-Filo or r-VSV-ZEBOV to enter the study.
Study: NCT00760669

Intervention type: DRUG
Intervention: Infliximab; observational study
Description: This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.

Intervention type: DRUG
Intervention: Methotrexate; observational study
Description: Participants with RA will receive methotrexate based on physician's clinical judgement.
Study: NCT03349892

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.
Study: NCT00109720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Consultant
Description: services of a Diabetes Self-Management Consultant

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Control Group
Description: Usual care plus results of metabolic assessments obtained during the study
Study: NCT03940547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of flour
Description: Infant and young child feeding education and provision of low AF porridge and groundnut flours from 6-18 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Promotion of flour
Description: Infant and young child feeding education and promotion of porridge and groundnut flours from 6-18 months
Study: NCT03220087

Intervention type: OTHER
Intervention: Data collection
Description: The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.

Intervention type: OTHER
Intervention: Data collection
Description: The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.
Study: NCT00999713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calfactant
Description: Endotracheal calfactant, up to 3 doses if subject qualifies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Air placebo
Description: Endotracheal air administration
Study: NCT03698890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Network-based home blood pressure monitor
Description: A network-based home blood pressure monitor will be loaned to patients in the intervention group, who will be asked to monitor their blood pressure at least once every week using the network based home blood pressure monitor, which automatically uploads measured blood pressure readings to the portal for care managers (CM) to review blood pressure readings and provide updates to the patient on blood pressure control. If a patient's blood pressure is elevated, the CM can titrate medications over the phone and provide follow up tele-consultation and necessary treatment.
Study: NCT02519309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virta Program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virta Program
Study: NCT03926156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
Study: NCT04640389

Intervention type: OTHER
Intervention: Cross-sectional study/no intervention
Description: Cross-sectional study/no intervention.

Intervention type: OTHER
Intervention: Cross-sectional study/no intervention
Description: Cross-sectional study/no intervention.
Study: NCT02016833

Intervention type: PROCEDURE
Intervention: Blood Sampling
Description: Sampling of 80mL of whole blood
Study: NCT02901366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-FYU-981
Description: 14C-FYU-981, (Oral single dosing)
Study: NCT04369222

Intervention type: OTHER
Intervention: Observational
Description: Maternal consumption of mild analgesics
Study: NCT01087112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother-Infant Psychoanalytic tmt
Description: Psychoanalytic sessions with mother and infant, at a median of 23 sessions 2 times weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Health Centre care
Description: Nurse calls at Child Health Centres (CHC), with regular paediatric checkups. The nurse was encouraged to promote attachment and to detect postnatal depressions. Appointments with a psychiatrist or therapist or child psychiatric psychologist was initiated in 1/3 of the cases. This was registered at the end-point interview.
Study: NCT03725163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy Enhanced Behavior Therapy (AEBT)
Description: This treatment approach blends traditional behavior therapy elements of habit reversal training and stimulus control techniques with the more contemporary behavioral elements of Acceptance and Commitment Therapy (ACT). The first phase of the treatment, clients are taught skills for stopping and preventing their unconscious pulling episodes. The second phase, clients are introduced to ACT. Unlike interventions that aim to change the type or frequency of pulling-related cognitions, this treatment uses strategies to change the function of these cognitions. Clients are taught to see urges for what they really are and to accept their pulling-related thoughts, feelings, and urges without fighting against them. Over the course of 10 session clients will learn to be aware of their pulling and warning signals, use self-management strategies for stopping and preventing pulling, stop fighting against their pulling-related urges and thoughts, and work toward increasing their quality of life.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy Enhanced Behavior Therapy (AEBT)
Description: This treatment approach blends traditional behavior therapy elements of habit reversal training and stimulus control techniques with the more contemporary behavioral elements of Acceptance and Commitment Therapy (ACT). The first phase of the treatment, clients are taught skills for stopping and preventing their unconscious pulling episodes. The second phase, clients are introduced to ACT. Unlike interventions that aim to change the type or frequency of pulling-related cognitions, this treatment uses strategies to change the function of these cognitions. Clients are taught to see urges for what they really are and to accept their pulling-related thoughts, feelings, and urges without fighting against them. Over the course of 10 session clients will learn to be aware of their pulling and warning signals, use self-management strategies for stopping and preventing pulling, stop fighting against their pulling-related urges and thoughts, and work toward increasing their quality of life.
Study: NCT02494466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: 4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: 4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: 4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
Study: NCT00603655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic load diet
Description: Low glycemic load diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High glycemic load diet
Description: High glycemic load diet
Study: NCT03431857

Intervention type: DEVICE
Intervention: TESS V2
Description: Patients requiring the TESS V2 prosthesis.
Study: NCT04195958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency will be determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.
Study: NCT03732508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome
Description: Irinotecan liposome intravenous infusion will be administered during the first day of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: SHR-1316 intravenous infusion will be administered during the first day of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil intravenous infusion will be administered during the first day of treatment.
Study: NCT04194281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Training [AOT]
Description: Parents are instructed to show their child repetitive arm, hand and finger movements in a playful and age-appropriate way for about 20 minutes a day, divided into several short sequences. AOT is to be carried out for four weeks at home by the parents and, if necessary, other caregivers. The parents receive instructions which contain background information on the possible importance of AOT for improving the functions of the upper limb, information about positions, promoting motivation, attention and interest as well as tips for promoting movement observation in everyday life.
Study: NCT04697121

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Combined Bergamot phytosome and Artichoke leaf dry extract
Description: 600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract. Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
Study: NCT02690805

Intervention type: DEVICE
Intervention: MR-compatible scinti-mammography (MRI-SMM) system
Study: NCT03575286

Intervention type: DIAGNOSTIC_TEST
Intervention: Pregnancy test
Description: Detects hormone (hCG, Human Chorionic Gonadotropin) produced by the body during pregnancy

Intervention type: DIAGNOSTIC_TEST
Intervention: Pregnancy test
Description: Detects hormone (hCG, Human Chorionic Gonadotropin) produced by the body during pregnancy
Study: NCT00737919

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant Stanol
Description: Plant stanols in margarines daily 2 grams

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant Sterol
Description: Plant sterols in margarines daily 2 grams